FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Scannell Robert 		2. Issuer Name and Ticker or Trading Symbol

ROCK CREEK PHARMACEUTICALS, INC. [ RCPI ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O ROCK CREEK PHARMACEUTICALS, INC., 2040 WHITFIELD AVE., SUITE 300 		3. Date of Earliest Transaction (MM/DD/YYYY)

11/17/2015
(Street)

SARASOTA, FL 34243
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                  307915   I   By Feehan Partners, LP   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options to Purchase Common Stock   $0.87   11/17/2015     A      2000         (2) 11/17/2025   Common Stock   2000   $0   2000   D    
Warrant (right to buy)   $3                    5/8/2019   5/8/2022   Common Stock   69831     69831   I   Feehan Partners, LP   (1)
Warrant (right to buy)   $3.75                    1/28/2015   1/27/2022   Common Stock   6003     6003   I   Feehan Partners, LP   (1)
Warrant (right to buy)   $25.00                    8/8/2014   8/8/2021   Common Stock   50000     50000   I   Feehan Partners, LP   (1)
Warrant (right to buy)   $25.00                    8/8/2014   8/8/2021   Common Stock   7000     7000   I   Feehan Partners, LP   (1)

Explanation of Responses:
( 1)  Feehan Partners, LP is a family limited partnership controlled by the reporting person.
( 2)  Options to purchase common stock, granted pursuant to the issuer's Third Amended and Restated 2008 Incentive Award Plan, are exercisable as follows: 50% on the first anniversary of the date of grant and 100% on the second anniversary of the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Scannell Robert
C/O ROCK CREEK PHARMACEUTICALS, INC.
2040 WHITFIELD AVE., SUITE 300
SARASOTA, FL 34243 		X



Signatures
/s/ Curt P. Creely, Attorney-in-Fact for Robert W. Scannell 11/25/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Rock Creek Pharmaceuticals (CE) Charts.
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Rock Creek Pharmaceuticals (CE) Charts.